system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Acinar Cells, Adalimumab, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Apoptosis, Cell Line, DNA Fragmentation, Electrophoresis, Polyacrylamide Gel, Enzyme-Linked Immunosorbent Assay, Etanercept, Gene Expression, Humans, Immunoglobulin G, Matrix Metalloproteinase 9, RNA, Messenger, Real-Time Polymerase Chain Reaction, Receptors, Tumor Necrosis Factor, Salivary Glands, Sjogren's Syndrome, Tumor Necrosis Factor-alpha.
user
Does targeting TNF-α suppress the production of MMP-9 in human salivary gland cells? Context: Tumour necrosis factor-α (TNF-α) is a pleiotropic cytokine that plays an essential role in inflammation and apoptosis. Our previous study suggested that TNF-α-induced activation of matrix metalloproteinase-9 (MMP-9) resulted in the destruction of acinar tissue in the salivary glands of patients with Sjögren's syndrome (SS) via disruption of the acinar cell-basement membrane. Recently, a wide array of biological agents has been designed to inhibit TNF, including etanercept and adalimumab. In this study, we demonstrate the suppressive effect of anti-TNF agents on TNF-α-induced MMP-9 production in NS-AV-AC, an immortalized human salivary gland acinar cell line. NS-AV-AC cells were treated with etanercept or adalimumab after TNF-α treatment. MMP-9 production and enzymatic activity were, respectively, visualized by real-time PCR and ELISA assay, and evaluated by gelatin zymography, and apoptosis was evaluated by DNA fragmentation assay. TNF-α induced the production of MMP-9 in NS-SV-AC cells. However, this production was greatly inhibited by treatment with etanercept or adalimumab. In addition, TNF-α-induced DNA fragmentation was prevented by treatment with etanercept or adalimumab.
assistant
These results may indicate that anti-TNF agents would have therapeutic efficacy for preventing destruction of the acinar structure in the salivary glands of patients with SS. Final Decision: yes